- NCIt
- C8990
Loading cancer entity…
Loading cancer entity…
Clinical trials
310 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (38)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04191460 | Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer(GuidedbyLight) | completed | Phase 2 | 31 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 |
| clinicaltrials |
| NCT02254278 | Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer | completed | Phase 2 | 316 | NRG OncologyOTHER | 4 | May 22, 2026 | clinicaltrials |
| NCT03370276 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT00939627 | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03993353 | Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 7 | University of California, San DiegoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03021993 | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | completed | Phase 2 | 17 | Medical University of South CarolinaOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02882282 | Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | completed | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma(NEOPBOSCC) | completed | Phase 2 | 68 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity(INSPIRE) | completed | Phase 2 | 105 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 4 | Jan 30, 2024 | clinicaltrials |
| NCT01914900 | Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | completed | Phase 2 | 14 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT01884259 | Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN(HNO-2) | completed | Phase 2 | 100 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT02873819 | Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | completed | Phase 2 | 80 | Gliknik Inc.INDUSTRY | 7 | Mar 8, 2022 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT01414426 | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | completed | Phase 2 | 20 | University of ChicagoOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT01175980 | Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 3, 2020 | clinicaltrials |
| NCT01044433 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01604772 | Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 1, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01316757 | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | completed | Phase 2 | 24 | Fox Chase Cancer CenterOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT01542931 | TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 256 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01256385 | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy(MAESTRO HN) | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Mar 27, 2017 | clinicaltrials |
| NCT00095628 | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2017 | clinicaltrials |
| NCT02007200 | Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01108042 | TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | completed | Phase 1 / Phase 2 | 71 | Orlando Guntinas-Lichius, Prof. Dr. med.OTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT01192204 | Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention | completed | Phase 1 / Phase 2 | 41 | Ohio State UniversityOTHER | 1 | Aug 14, 2015 | clinicaltrials |
| NCT00458978 | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00114283 | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00507767 | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00103259 | Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 71 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00513435 | Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2014 | clinicaltrials |
| NCT00780312 | Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer(HOHF) | completed | Phase 2 | 97 | Rigshospitalet, DenmarkOTHER | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00096512 | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00033618 | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00077428 | Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials